State Street SPDR S&P Biotech ETF
932 hedge funds and large institutions have $19.6B invested in State Street SPDR S&P Biotech ETF in 2026 Q2 according to their latest regulatory filings, with 175 funds opening new positions, 325 increasing their positions, 230 reducing their positions, and 48 closing their positions.
265% more first-time investments, than exits
New positions opened: 175 | Existing positions closed: 48
41% more repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 230
32% more funds holding in top 10
Funds holding in top 10: 22 → 29 (+7)
17% more capital invested
Capital invested by funds: $16.7B → $19.6B (+$2.87B)
15% more call options, than puts
Call options by funds: $3.61B | Put options by funds: $3.13B
14% more funds holding
Funds holding: 816 → 932 (+116)
35.41% less ownership
Funds ownership: 218.39% → 182.98% (-35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$188M |
| 2 |
Two Sigma Investments
New York
|
+$156M |
| 3 |
Citigroup
New York
|
+$128M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$102M |
| 5 |
JG
Jain Global
New York
|
+$80M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$598M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$592M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$534M |
| 4 |
Morgan Stanley
New York
|
-$202M |
| 5 |
D.E. Shaw & Co
New York
|
-$140M |
XBI Hedge Fund Activity: Q2 2026 in Review
932 of the 8,287 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2026, worth a combined $19.6B — up 17% from $16.7B a quarter earlier.
Buyers outnumbered sellers: 175 funds opened new XBI positions and 48 closed out — a net gain of 127 holders — while 325 added to existing stakes and 230 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $188M. The largest seller was JP Morgan Chase, cutting an estimated $598M.
- 932 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2026, up from 816 in Q1 2026.
- Funds reported $19.6B of State Street SPDR S&P Biotech ETF stock for Q2 2026, up 17% quarter-over-quarter.
- 175 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2026 and 48 closed out, a net change of +127 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2026 was Goldman Sachs, an estimated $188M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2026 was JP Morgan Chase, an estimated $598M sold.
Based on aggregated 13F filings for Q2 2026.